# Lando Biomaterials

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lando-biomaterials

- Industry: Materials
- Headquarters: Shenzhen, China
- Website: www.landobiom.com
- Total disclosed funding: $16M
- Latest round: Series C (Dec 22, 2017)
- Investors on record: 5

## About

Established in 2010 and based in Shenzhen, China, Lando Biomaterials operates as a medical materials provider that provides medical treatment and auxiliary materials for injuries and orthopedics. The chairman, president and chief scientist officer of this company, She Zhending, is a PhD from Tsinghua University and was the executive deputy director of the Key Laboratory of Biomedical Materials at Tsinghua University Research Institute in Shenzhen.

The company's main business is the research and development of high-end biomedical materials for applications in wound care, oral health, digestive tract, neural/muscular repair, and aesthetic medicine. The company's self-developed products include Lando® double-layer artificial dermis, Lando® oral absorbable biomembrane, and Lando® bone graft materials.

The company generates revenue by providing biomedical materials and solutions.

## Funding rounds

- Series C, Dec 22, 2017 — Leaguer Group
- Series B, Jun 5, 2017, $5.9M — Share Capital
- Series A, Dec 23, 2015, $5.4M — Albatross Venture, Suzhou Zhongjingxin Investment Management
- Series A, Jul 1, 2014, $4.5M — Leaguer Group, Tsing-Yuan Capital
- Angel, May 25, 2011 — Leaguer Group

## Investors

- Leaguer Group (https://capitalatlas.ai/funds/leaguer-group) — Angel, Series A, Series C
- Tsing-Yuan Capital (https://capitalatlas.ai/funds/tsing-yuan-capital) — Series A
- Albatross Venture (https://capitalatlas.ai/funds/albatross-venture) — Series A
- Suzhou Zhongjingxin Investment Management (https://capitalatlas.ai/funds/suzhou-zhongjingxin-investment-management) — Series A
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series B